The impact of immediate breast reconstruction on the time to delivery of adjuvant therapy: the iBRA-2 study

O'Connell, Rachel L., Rattay, Tim, Dave, Rajiv V., Trickey, Adam, Skillman, Joanna, Barnes, Nicola L. P., Gardiner, Matthew, Harnett, Adrian, Potter, Shelley, Holcombe, Chris, , on behalf of the iBRA-2 Steering Group and , the Breast Reconstruction Research Collaborative (2019) The impact of immediate breast reconstruction on the time to delivery of adjuvant therapy: the iBRA-2 study. British Journal of Cancer, 120. 883–895. ISSN 0007-0920

[img]
Preview
PDF (Published_Version) - Published Version
Available under License Creative Commons Attribution.

Download (468kB) | Preview

Abstract

Background: Immediate breast reconstruction (IBR) is routinely offered to improve quality-of-life for women requiring mastectomy, but there are concerns that more complex surgery may delay adjuvant oncological treatments and compromise long-term outcomes. High-quality evidence is lacking. The iBRA-2 study aimed to investigate the impact of IBR on time to adjuvant therapy. Methods: Consecutive women undergoing mastectomy ± IBR for breast cancer July–December, 2016 were included. Patient demographics, operative, oncological and complication data were collected. Time from last definitive cancer surgery to first adjuvant treatment for patients undergoing mastectomy ± IBR were compared and risk factors associated with delays explored. Results: A total of 2540 patients were recruited from 76 centres; 1008 (39.7%) underwent IBR (implant-only [n = 675, 26.6%]; pedicled flaps [n = 105,4.1%] and free-flaps [n = 228, 8.9%]). Complications requiring re-admission or re-operation were significantly more common in patients undergoing IBR than those receiving mastectomy. Adjuvant chemotherapy or radiotherapy was required by 1235 (48.6%) patients. No clinically significant differences were seen in time to adjuvant therapy between patient groups but major complications irrespective of surgery received were significantly associated with treatment delays. Conclusion: IBR does not result in clinically significant delays to adjuvant therapy, but post-operative complications are associated with treatment delays. Strategies to minimise complications, including careful patient selection, are required to improve outcomes for patients.

Item Type: Article
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 03 Sep 2020 23:57
Last Modified: 22 Sep 2020 23:57
URI: https://ueaeprints.uea.ac.uk/id/eprint/76755
DOI: 10.1038/s41416-019-0438-1

Actions (login required)

View Item View Item